Alkermes (ALKS) Competitors $26.55 -0.05 (-0.19%) Closing price 04:00 PM EasternExtended Trading$26.56 +0.00 (+0.02%) As of 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALKS vs. ABEO, MEDP, OMCL, AMN, INCY, UTHR, NBIX, EXEL, BMRN, and EXASShould you be buying Alkermes stock or one of its competitors? The main competitors of Alkermes include Abeona Therapeutics (ABEO), Medpace (MEDP), Omnicell (OMCL), AMN Healthcare Services (AMN), Incyte (INCY), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), and Exact Sciences (EXAS). These companies are all part of the "medical" sector. Alkermes vs. Its Competitors Abeona Therapeutics Medpace Omnicell AMN Healthcare Services Incyte United Therapeutics Neurocrine Biosciences Exelixis BioMarin Pharmaceutical Exact Sciences Alkermes (NASDAQ:ALKS) and Abeona Therapeutics (NASDAQ:ABEO) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk. Which has more volatility and risk, ALKS or ABEO? Alkermes has a beta of 0.47, meaning that its stock price is 53% less volatile than the S&P 500. Comparatively, Abeona Therapeutics has a beta of 1.55, meaning that its stock price is 55% more volatile than the S&P 500. Is ALKS or ABEO more profitable? Alkermes has a net margin of 23.15% compared to Abeona Therapeutics' net margin of 0.00%. Alkermes' return on equity of 24.86% beat Abeona Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Alkermes23.15% 24.86% 17.14% Abeona Therapeutics N/A -118.82%-52.48% Which has preferable valuation and earnings, ALKS or ABEO? Alkermes has higher revenue and earnings than Abeona Therapeutics. Abeona Therapeutics is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlkermes$1.56B2.81$367.07M$2.0812.76Abeona Therapeutics$3.50M93.40-$63.73M-$1.27-5.03 Does the media favor ALKS or ABEO? In the previous week, Alkermes had 12 more articles in the media than Abeona Therapeutics. MarketBeat recorded 19 mentions for Alkermes and 7 mentions for Abeona Therapeutics. Alkermes' average media sentiment score of 0.97 beat Abeona Therapeutics' score of 0.15 indicating that Alkermes is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alkermes 10 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Abeona Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer ALKS or ABEO? Alkermes presently has a consensus price target of $41.08, suggesting a potential upside of 54.74%. Abeona Therapeutics has a consensus price target of $19.25, suggesting a potential upside of 201.25%. Given Abeona Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Abeona Therapeutics is more favorable than Alkermes.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alkermes 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.83Abeona Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders have more ownership in ALKS or ABEO? 95.2% of Alkermes shares are owned by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are owned by institutional investors. 4.4% of Alkermes shares are owned by insiders. Comparatively, 6.9% of Abeona Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryAlkermes beats Abeona Therapeutics on 12 of the 17 factors compared between the two stocks. Get Alkermes News Delivered to You Automatically Sign up to receive the latest news and ratings for ALKS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALKS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALKS vs. The Competition Export to ExcelMetricAlkermesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.39B$3.02B$5.57B$9.48BDividend YieldN/A2.42%4.31%4.13%P/E Ratio12.765.8618.7821.62Price / Sales2.81306.36441.7495.96Price / Cash10.0342.1735.8458.51Price / Book2.707.818.085.58Net Income$367.07M-$54.52M$3.26B$265.35M7 Day Performance-4.94%-0.87%-0.73%-0.89%1 Month Performance-7.65%13.63%5.52%4.98%1 Year Performance-3.45%11.57%28.79%23.50% Alkermes Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALKSAlkermes4.7721 of 5 stars$26.55-0.2%$41.08+54.7%-4.5%$4.39B$1.56B12.761,800Analyst RevisionABEOAbeona Therapeutics3.8772 of 5 stars$6.62+1.4%$19.25+190.8%+40.7%$338.66MN/A-5.2190News CoverageUpcoming EarningsMEDPMedpace4.2441 of 5 stars$453.05+1.2%$411.10-9.3%+15.7%$12.73B$2.23B33.685,900Positive NewsOMCLOmnicell3.62 of 5 stars$29.00+2.6%$45.33+56.3%-23.8%$1.36B$1.11B63.043,670Earnings ReportAMNAMN Healthcare Services4.3036 of 5 stars$19.71-0.5%$32.08+62.8%-71.4%$754.42M$2.98B-4.552,968Upcoming EarningsINCYIncyte4.7693 of 5 stars$70.16-0.1%$74.47+6.1%+25.4%$13.58B$4.24B219.262,617Analyst UpgradeUTHRUnited Therapeutics4.9558 of 5 stars$298.14-2.1%$383.08+28.5%-6.4%$13.45B$2.99B11.901,305Positive NewsEarnings ReportAnalyst RevisionNBIXNeurocrine Biosciences4.9668 of 5 stars$133.71+1.2%$163.87+22.6%-13.1%$13.23B$2.36B45.331,800Trending NewsEarnings ReportAnalyst RevisionEXELExelixis4.9482 of 5 stars$44.39-2.7%$45.33+2.1%+59.3%$12.11B$2.17B20.181,147High Trading VolumeBMRNBioMarin Pharmaceutical4.9956 of 5 stars$58.14-1.5%$93.74+61.2%-23.0%$11.15B$2.85B21.613,040Trending NewsAnalyst ForecastAnalyst RevisionEXASExact Sciences4.4471 of 5 stars$48.04-0.9%$70.50+46.8%-15.1%$9.06B$2.83B-8.727,000News CoveragePositive News Related Companies and Tools Related Companies Abeona Therapeutics Alternatives Medpace Alternatives Omnicell Alternatives AMN Healthcare Services Alternatives Incyte Alternatives United Therapeutics Alternatives Neurocrine Biosciences Alternatives Exelixis Alternatives BioMarin Pharmaceutical Alternatives Exact Sciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALKS) was last updated on 8/6/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredGuess Who the Gvt Could Partner With Next?The Government Just Made a $400M Bet. Who's Next? A $100 trillion wealth shift is quietly underway... and t...Stansberry Research | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullis...Golden Portfolio | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alkermes plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Alkermes With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
